Kura Oncology’s Darlifarnib Combo Achieves 44% Response Rate in Difficult-to-Treat RCC—Signals Potential to Overcome Drug Resistance
Market Chameleon (Fri, 17-Apr 11:46 AM)
Darlifarnib Plus Cabozantinib Shows Strong Response Rates in Heavily Pretreated Renal Cell Carcinoma—44% ORR and 94% DCR Stand Out
Market Chameleon (Fri, 17-Apr 7:28 AM)
Kura Oncology’s Early KOMZIFTI Revenue Momentum and Strong Balance Sheet Stand Out Amid 2025 Results
Market Chameleon (Thu, 5-Mar 8:45 AM)
